A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this years survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions
These applications take time to process
By combining all three receptor targets, Retatrutide allows researchers to study the convergence of incretin biology and glucagon-driven energy expenditure in a single compound, opening research questions that cannot be addressed with any dual or single-receptor agonist
The same 10 mg vial with 2 mL of water yields 5,000 mcg/mL, making it easier to measure smaller doses
As of July 1, there are 3,848 pending actions in the MDL
Lastly, a combination of exendin-4 and metformin has been shown to attenuate different forms of cancer at a more noticeable rate [94, 95]